ANVS
Annovis Bio, Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Sell
-47/100
Last price
1.18
▼ 0.02 (1.67%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
1.20
Day high
1.24
Day low
1.17
Volume
538.71K
Market cap
$50.36M
P/E (TTM)
—
52W range
1.04 – 5.50
Trailing performance
Returnvs SPY
1W
-9.23%
-11.2%
1M
-15.11%
-16.3%
3M
-40.70%
-45.2%
6M
-48.02%
-66.2%
YTD
-65.90%
-80.1%
1Y
-46.85%
-63.3%
3Y
-87.57%
-169.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ANVS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
5.02M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| May 20, 26 | HOFFMAN MICHAEL B Director |
BUY | 76.34K | $142.78K | Direct |
| Apr 2, 26 | HOFFMAN MICHAEL B Director |
BUY | 713.80K | $1.50M | Direct |
| Dec 8, 25 | HOFFMAN MICHAEL B Director |
BUY | 45.00K | $193.79K | Direct |
| Nov 24, 25 | HOFFMAN MICHAEL B Director |
BUY | 39.20K | $159.89K | Direct |
| Nov 24, 25 | HOFFMAN MICHAEL B Director |
BUY | 39.20K | $159.89K | Direct |
| Nov 21, 25 | HOFFMAN MICHAEL B Director |
BUY | 20.00K | $69.90K | Direct |
| Nov 14, 25 | HOFFMAN MICHAEL B Director |
BUY | 15.00K | $31.65K | Direct |
| Oct 28, 25 | MACCECCHINI MARIA-LUISA Chief Executive Officer |
BUY | 97.56K | $200.00K | Direct |
| Oct 28, 25 | HOFFMAN MICHAEL B Director |
BUY | 975.61K | $2.00M | Direct |
| Sep 10, 25 | BRUCK CLAUDINE Director |
CONVERSION | 7.14K | $1.00K | Direct |
| Aug 29, 25 | HOFFMAN MICHAEL B Director |
STOCK | 15.00K | $34.35K | Direct |
| Aug 19, 25 | HOFFMAN MICHAEL B Director |
STOCK | 18.64K | $48.28K | Direct |
| Jun 16, 25 | WALSH ANDREW Officer |
STOCK | 500 | $1.45K | Direct |
| Jun 13, 25 | HOFFMAN MICHAEL B Director |
STOCK | 25.00K | $70.00K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BRUCK CLAUDINE |
Director | 13.71K | Conversion of Exercise of derivative security |
HOFFMAN MICHAEL B |
Director | 3.59M | Purchase |
MACCECCHINI MARIA-LUISA |
Chief Executive Officer | 1.21M | Purchase |
MCCARTHY REID S. |
Director | 9.30K | Stock Award(Grant) |
WALSH ANDREW |
Officer | 500 | Stock Award(Grant) |
Fundamentals
Market cap$50.36M
Enterprise value$31.55M
Revenue (TTM)—
Gross profit—
EBITDA—
Net income$-49.52M
EPS (TTM)$-1.75
Free cash flow$-23.79M
Total cash$18.73M
Total debt$0
Book value / share$-0.10
Shares outstanding42.68M
Float35.47M
Short % of float15.48%
Dividend yield0.00%
Beta (5Y)1.23
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.37
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-703.68%
Return on assets-142.36%
Debt / equity—
Current ratio3.47
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $25.22M | $20.00M | $38.79M | $16.52M | +26.1% |
| Selling, general & admin | $4.48M | $6.70M | $6.24M | $9.00M | -33.1% |
| Total operating expense | $29.70M | $26.69M | $45.04M | $25.51M | +11.2% |
| Operating income | -$29.70M | -$26.69M | -$45.04M | -$25.51M | -11.2% |
| Net interest income | $699.06K | -$1.52M | $667.90K | $182.71K | +146.0% |
| Pre-tax income | -$28.85M | -$24.59M | -$56.20M | -$25.33M | -17.3% |
| Net income | -$28.85M | -$24.59M | -$56.20M | -$25.33M | -17.3% |
| Net income to common | -$28.85M | -$24.59M | -$56.20M | -$25.33M | -17.3% |
| Basic EPS | -1.40 | -2.02 | -6.23 | -3.10 | +30.7% |
| Diluted EPS | -1.40 | -2.31 | -6.23 | -3.10 | +39.4% |
| EBIT | -$29.70M | -$26.69M | -$45.04M | -$25.51M | -11.2% |
| EBITDA | -$29.70M | -$26.69M | -$45.04M | -$25.51M | -11.2% |
| Basic shares | 20.55M | 12.18M | 9.02M | 8.16M | +68.7% |
| Diluted shares | 20.55M | 12.24M | 9.02M | 8.16M | +68.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $19.53M | $10.55M | $5.75M | $28.38M | +85.1% |
| Cash & short-term investments | $19.53M | $10.55M | $5.75M | $28.38M | +85.1% |
| Total current assets | $21.08M | $13.93M | $10.21M | $36.02M | +51.4% |
| Total assets | $21.08M | $13.93M | $10.21M | $36.02M | +51.4% |
| Total current liabilities | $3.64M | $3.88M | $4.28M | $7.70M | -6.3% |
| Total liabilities | $4.23M | $4.62M | $17.96M | $7.70M | -8.4% |
| Retained earnings | -$163.70M | -$134.85M | -$110.26M | -$54.05M | -21.4% |
| Shareholder equity | $16.85M | $9.31M | -$7.75M | $28.32M | +81.0% |
| Working capital | $17.45M | $10.04M | $5.93M | $28.32M | +73.7% |
| Net tangible assets | $16.85M | $9.31M | -$7.75M | $28.32M | +81.0% |
| Shares issued | 27.20M | 14.14M | 10.52M | 8.16M | +92.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$28.85M | -$24.59M | -$56.20M | -$25.33M | -17.3% |
| Stock-based compensation | $1.80M | $3.84M | $4.63M | $9.15M | -53.1% |
| Change in working capital | $1.58M | $681.71K | -$228.60K | -$1.14M | +131.6% |
| Operating cash flow | -$25.62M | -$21.89M | -$39.97M | -$17.31M | -17.0% |
| Financing cash flow | $34.60M | $26.69M | $17.34M | $4.61K | +29.6% |
| Free cash flow | -$25.62M | -$21.89M | -$39.97M | -$17.31M | -17.0% |
| End cash position | $19.53M | $10.55M | $5.75M | $28.38M | +85.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $12.01M | $16.72M | $8.75M | $6.29M | $5.16M | — | -28.2% |
| Selling, general & admin | $2.37M | $1.29M | $955.15K | $1.14M | $1.11M | — | +83.5% |
| Total operating expense | $14.38M | $18.01M | $9.71M | $7.43M | $6.27M | — | -20.2% |
| Operating income | -$14.38M | -$18.01M | -$9.71M | -$7.43M | -$6.27M | — | +20.2% |
| Net interest income | -$1.43M | $137.80K | $167.74K | $152.32K | $191.40K | — | -1,137.1% |
| Pre-tax income | -$14.82M | -$17.61M | -$9.83M | -$7.26M | -$6.22M | — | +15.8% |
| Net income | -$14.82M | -$17.61M | -$9.83M | -$7.26M | -$6.22M | — | +15.8% |
| Net income to common | -$14.82M | -$17.61M | -$9.83M | -$7.26M | -$6.22M | — | +15.8% |
| Basic EPS | -0.40 | -0.63 | — | -0.37 | -0.32 | -0.32 | +36.5% |
| Diluted EPS | -0.40 | -0.63 | — | -0.37 | -0.32 | -0.32 | +36.5% |
| EBIT | -$14.38M | -$18.01M | -$9.71M | -$7.43M | -$6.27M | — | +20.2% |
| EBITDA | -$14.38M | -$18.01M | -$9.71M | -$7.43M | -$6.27M | — | +20.2% |
| Basic shares | 37.52M | 27.85M | — | 19.69M | 19.49M | 17.43M | +34.7% |
| Diluted shares | 37.52M | 27.85M | — | 19.69M | 19.49M | 17.43M | +34.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $18.73M | $14.22M | $19.53M | $15.29M | $17.13M | +31.7% |
| Cash & short-term investments | $18.73M | $14.22M | $19.53M | $15.29M | $17.13M | +31.7% |
| Total current assets | $22.04M | $16.24M | $21.08M | $17.19M | $21.45M | +35.7% |
| Total assets | $22.04M | $16.24M | $21.08M | $17.19M | $21.45M | +35.7% |
| Total current liabilities | $6.36M | $12.79M | $3.64M | $3.73M | $2.81M | -50.3% |
| Total liabilities | $26.29M | $13.12M | $4.23M | $4.03M | $3.12M | +100.4% |
| Retained earnings | -$196.13M | -$181.31M | -$163.70M | -$153.87M | -$146.61M | -8.2% |
| Shareholder equity | -$4.25M | $3.13M | $16.85M | $13.16M | $18.33M | -236.1% |
| Working capital | $15.68M | $3.45M | $17.45M | $13.46M | $18.65M | +354.0% |
| Net tangible assets | -$4.25M | $3.13M | $16.85M | $13.16M | $18.33M | -236.1% |
| Shares issued | 42.61M | 28.54M | 27.20M | 20.19M | 19.49M | +49.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$14.82M | -$17.61M | -$9.83M | -$7.26M | -$6.22M | +15.8% |
| Stock-based compensation | $1.61M | $182.82K | $356.52K | $444.65K | $496.62K | +779.9% |
| Change in working capital | -$7.72M | $8.68M | $254.85K | $3.35M | $477.55K | -188.9% |
| Operating cash flow | -$21.91M | -$9.01M | -$8.93M | -$3.49M | -$5.11M | -143.2% |
| Financing cash flow | $26.42M | $3.70M | $13.17M | $1.64M | $0 | +614.5% |
| Free cash flow | -$21.91M | -$9.01M | -$8.93M | -$3.49M | -$5.11M | -143.2% |
| End cash position | $18.73M | $14.22M | $19.53M | $15.29M | $17.13M | +31.7% |
Options analytics
Put / call volume
0.34
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
0.50
-57.6% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
160
Contracts, this expiry
Put volume
54
Contracts, this expiry
Heaviest call OI
0.50
0 contracts
Heaviest put OI
1.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.46 | -0.40 | +13.0% |
| Mar 2026 | -0.35 | -0.63 | -80.0% |
| Dec 2025 | -0.30 | -0.39 | -30.0% |
| Sep 2025 | -0.37 | -0.37 | 0.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.33 | 2 | $0 | 0.0% |
| Next quarter | -0.24 | 2 | $0 | 0.0% |
| Current year | -1.45 | 2 | $0 | 0.0% |
| Next year | -0.86 | 2 | $0 | 0.0% |
Analyst targets & ownership
Mean target$10.50
High target$17.00
Low target$7.00
Implied upside789.83%
Analyst count4
ConsensusNONE
Strong buy / Buy1 / 3
Hold0
Sell / Strong sell0 / 0
Held by insiders11.79%
Held by institutions27.86%
Institutions holding70
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.26
-6.27% from price
SMA 20
1.21
-2.12% from price
SMA 50
1.53
-22.88% from price
SMA 100
1.69
-30.26% from price
SMA 200
2.15
-45.04% from price
EMA 12
1.24
-4.46% from price
EMA 26
1.32
-10.55% from price
EMA 50
1.46
-19.10% from price
RSI (14)
38.4
Neutral
MACD (12,26,9)
-0.08
Hist 0.01
ATR (14)
0.09
7.63% of price
Realised vol 30D
86.3%
Annualised
Bollinger upper
1.37
20, 2σ
Bollinger lower
1.04
20, 2σ
50 / 200 cross
Death
1.53 vs 2.15
Trend bias
Below 200
-45.04%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.78
More volatile than market
Correlation to SPY
0.25
Largely independent
Realised vol 30D
86.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-79.6%
Peak to trough
Max drawdown 5Y
-97.2%
Peak to trough
ATR 14
0.09
7.63% of price
Beta (reported)
1.23
5Y monthly, from filing
Short interest
Shares short
6.02M
Prior 4.96M
Change vs prior
+21.3%
Shorts adding
% of float
15.48%
Elevated
% of shares out
14.11%
Against total outstanding
Days to cover
5.1
Crowded exit
Float
35.47M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 28, 26 | Roth Capital | MAINTAINED | Buy | Buy |
| Aug 18, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Jul 8, 26 | Roth Capital | INITIATED | — | Buy |
| Apr 14, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Sep 30, 25 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Sep 3, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 9, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 15, 25 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Feb 10, 25 | D. Boral Capital | DOWNGRADE | Buy | Hold |
| Nov 11, 24 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Nov 11, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 25, 24 | Maxim Group | UPGRADE | Hold | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Proxy Statements
DEF 14A · 2026-09-11
Proxy Statements
PRE 14A · 2026-08-25
Periodic Financial Reports
10-Q · 2026-08-14
Corporate Changes & Voting Matters
8-K · 2026-07-10
Corporate Changes & Voting Matters
8-K · 2026-06-17
Corporate Changes & Voting Matters
8-K · 2026-05-20
Periodic Financial Reports
10-Q · 2026-05-15
Proxy Statements
DEF 14A · 2026-04-30
Headlines
Parkinson's Disease Market Poised for Expansion During the Forecast Period (2026-2036) Amid JUVMO Approval and Emerging Therapeutic Innovations | DelveInsight
PR Newswire · 20h ago
Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease
GlobeNewswire · 14d ago
Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks · 29d ago
Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA
MarketBeat · 34d ago
Annovis to Host Corporate Update Webinar on September 2, 2026
GlobeNewswire · 43d ago
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
GlobeNewswire · 54d ago
The Next Billion-Dollar Opportunity in Alzheimer's Disease Market: 6 Pipeline Therapies to Watch | DelveInsight
PR Newswire · 62d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.